Olaratumab
- Generic Name
- Olaratumab
- Brand Names
- Lartruvo
- Drug Type
- Biotech
- CAS Number
- 1024603-93-7
- Unique Ingredient Identifier
- TT6HN20MVF
- Background
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.
- Indication
用于治疗软组织肉瘤。
- Associated Conditions
- Soft Tissue Sarcoma
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT03994627
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Kaiser Permanente West Los Angeles, Los Angeles, California, United States
🇺🇸Ironwood Cancer & Research Centers, Glendale, Arizona, United States
Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 28
- Registration Number
- NCT03985722
- Locations
- 🇪🇸
GEIS, Madrid, Spain
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
- Conditions
- Advanced Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Target Recruit Count
- 2
- Registration Number
- NCT03698227
- Locations
- 🇩🇪
Medizinische Fakultät Carl Gustav Carus Medizinische Klinik I Internistische Onkologie, Dresden, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Helios Klinikum Berlin-Buch Klinik für Onkologie und Palliativmedizin, Berlin, Germany
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
- Conditions
- Leiomyosarcoma
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- University of Miami
- Registration Number
- NCT03437070
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT03283696
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
🇩🇪Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 41
- Registration Number
- NCT03126591
- Locations
- 🇫🇷
Gustave Roussy, Villejuif Cedex, France
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇧🇪Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 184
- Registration Number
- NCT03086369
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 51
- Registration Number
- NCT02783599
- Locations
- 🇺🇸
Moffitt Cancer Center & Research Inst, Tampa, Florida, United States
🇬🇧For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
🇺🇸Kansas City Cancer Center, Overland Park, Kansas, United States
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
- Conditions
- Neoplasm Metastasis
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT02677116
- Locations
- 🇺🇸
St Jude Childrens Research Hospital, Memphis, Tennessee, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Childrens Hospital of Los Angeles, Los Angeles, California, United States
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 310
- Registration Number
- NCT02659020
- Locations
- 🇺🇸
Georgia Cancer Specialists PC, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.